Skip to main content

Advertisement

SpringerLink
Log in

Kolonkarzinom und Gallengangskarzinom bei primär sklerosierender Cholangitis

Colon cancer and cholangiocarcinoma in primary sclerosing cholangitis

  • Schwerpunkt
  • Published:
Der Gastroenterologe Aims and scope

Zusammenfassung

Die primär sklerosierende Cholangitis (PSC) ist mit einem deutlich erhöhten Risiko hepatobiliärer und kolorektaler Karzinome assoziiert. Einheitliche Überwachungsprogramme bei Patienten mit PSC zur Detektion kolorektaler Karzinome sowie eines Cholangiokarzinoms (CC) sind bisher nicht etabliert. Neben der Labordiagnostik werden bildgebende und komplexe endoskopische Verfahren in bestimmten Zeitintervallen eingesetzt, um eine frühzeitige CC-Diagnose zu stellen. Bei gleichzeitig bestehender chronisch-entzündlicher Darmerkrankung sind jährliche Vorsorgekoloskopien erforderlich. Die Lebertransplantation als potenziell kuratives Therapieverfahren der PSC muss frühzeitig diskutiert und ständig reevaluiert werden. In dieser Übersichtsarbeit liegt der Schwerpunkt auf risikoadaptierten Überwachungsstrategien für das kolorektale sowie das Cholangiokarzinom.

Abstract

Primary sclerosing cholangitis (PSC) is associated with an increased risk of hepatobiliary and colorectal malignancies. Established surveillance protocols for colorectal cancer and cholangiocarcinoma are still lacking and the diagnosis of cholangiocarcinoma remains challenging. Only extensive laboratory diagnostics, imaging and complex endoscopic procedures facilitate an early diagnosis of cholangiocarcinoma. In cases of inflammatory bowel disease an annual surveillance colonoscopy is recommended. Liver transplantation as the only curative treatment option of PSC should be discussed at an early stage and continuously re-evaluated. This review article focuses on risk-adapted surveillance strategies for colorectal cancer and cholangiocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Alvaro D (2009) Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 25: 279–284

    Article  CAS  PubMed  Google Scholar 

  2. Bergquist A, Ekbom A, Olsson R et al (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36: 321–327

    Article  PubMed  Google Scholar 

  3. Boberg KM, Bergquist A, Mitchell S et al (2002) Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 37: 1205–1211

    Article  CAS  PubMed  Google Scholar 

  4. Boonstra K, Weersma RK, Erpecum KJ van et al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58: 2045–2055

    Article  CAS  PubMed  Google Scholar 

  5. Braden B, Halliday J, Aryasingha S et al (2012) Risk for colorectal neoplasia in patients with colonic Crohn’s disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 10: 303–308

    Article  PubMed  Google Scholar 

  6. Broome U, Olsson R, Loof L et al (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610–615

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Dignass A, Preiss JC, Aust DE et al (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 49: 1276–1341

    Article  CAS  PubMed  Google Scholar 

  8. Eaton JE, Thackeray EW, Lindor KD (2012) Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 107: 431–439

    Article  PubMed  Google Scholar 

  9. Gizard E, Ford AC, Bronowicki JP et al (2014) Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther 40: 3–15

    Article  CAS  PubMed  Google Scholar 

  10. Heinzow HS, Kammerer S, Rammes C et al (2014) Comparative analysis of ERCP, IDUS, EUS and CT in predicting malignant bile duct strictures. World J Gastroenterol 20: 10495–10503

    Article  PubMed Central  PubMed  Google Scholar 

  11. Kalaitzakis E, Sturgess R, Kaltsidis H et al (2014) Diagnostic utility of single-user peroral cholangioscopy in sclerosing cholangitis. Scand J Gastroenterol 49: 1237–1244

    Article  PubMed  Google Scholar 

  12. Kim WR, Therneau TM, Wiesner RH et al (2000) A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75: 688–694

    Article  CAS  PubMed  Google Scholar 

  13. Lankisch TO, Metzger J, Negm AA et al (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53: 875–884

    Article  CAS  PubMed  Google Scholar 

  14. Li C, Wang W, Ding H et al (2013) Value of contrast-enhanced sonography in the diagnosis of peripheral intrahepatic cholangiocarcinoma. J Clin Ultrasound 39: 447–453

    Article  CAS  Google Scholar 

  15. Li L, Masica D, Ishida M et al (2014) Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology 60: 896–907

    Article  CAS  PubMed  Google Scholar 

  16. Lindkvist B, Benito de Valle M, Gullberg B et al (2010) Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 52: 571–577

    Article  PubMed  Google Scholar 

  17. Lindstrom L, Lapidus A, Ost A et al (2011) Increased risk of colorectal cancer and dysplasia in patients with Crohn’s colitis and primary sclerosing cholangitis. Dis Colon Rectum 54: 1392–1397

    Article  PubMed  Google Scholar 

  18. Loftus EV Jr, Harewood GC, Loftus CG et al (2005) PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54: 91–96

    Article  PubMed Central  PubMed  Google Scholar 

  19. Lundqvist K, Broome U (1997) Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 40: 451–456

    Article  CAS  PubMed  Google Scholar 

  20. Lutz HH, Wasmuth HE, Streetz K et al (2012) Endoscopic ultrasound as an early diagnostic tool for primary sclerosing cholangitis: a prospective pilot study. Endoscopy 44: 934–939

    Article  CAS  PubMed  Google Scholar 

  21. Marchesa P, Lashner BA, Lavery IC et al (1997) The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 92: 1285–1288

    CAS  PubMed  Google Scholar 

  22. Metzger J, Negm AA, Plentz RR et al (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 62: 122–130

    Article  CAS  PubMed  Google Scholar 

  23. Munkholm P (2003) Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2): 1–5

    Article  PubMed  Google Scholar 

  24. Nehls O, Gregor M, Klump B (2004) Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24: 139–154

    Article  CAS  PubMed  Google Scholar 

  25. Pardi DS, Loftus EV Jr, Kremers WK et al (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: 889–893

    Article  CAS  PubMed  Google Scholar 

  26. Rudolph G, Gotthardt D, Kloeters-Plachky P et al (2010) In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 53: 313–317

    Article  PubMed  Google Scholar 

  27. Sangfelt P, Sundin A, Wanders A et al (2014) Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET. J Hepatol

  28. Shetty K, Rybicki L, Brzezinski A et al (1999) The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 94: 1643–1649

    Article  CAS  PubMed  Google Scholar 

  29. Singh S, Edakkanambeth Varayil J, Loftus EV Jr et al (2013) Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl 19: 1361–1369

    Article  PubMed  Google Scholar 

  30. Soetikno RM, Lin OS, Heidenreich PA et al (2002) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56: 48–54

    Article  PubMed  Google Scholar 

  31. Stahlberg D, Veress B, Tribukait B et al (2003) Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 46: 770–778

    Article  PubMed  Google Scholar 

  32. Tischendorf JJ, Meier PN, Strassburg CP et al (2006) Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 41: 1227–1234

    Article  PubMed  Google Scholar 

  33. Trikudanathan G, Navaneethan U, Njei B et al (2014) Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 79: 783–789

    Article  PubMed  Google Scholar 

  34. Tsaitas C, Semertzidou A, Sinakos E (2014) Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol 6: 178–187

    Article  PubMed Central  PubMed  Google Scholar 

  35. Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345–1353

    Article  CAS  PubMed  Google Scholar 

  36. Venkatesh PG, Navaneethan U, Shen B et al (2013) Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci 58: 850–857

    Article  CAS  PubMed  Google Scholar 

  37. Weismüller T, Strassburg C, Manns M et al (2012) Sklerosierende Cholangitiden. Gastroenterologe 7: 483–492

    Article  Google Scholar 

  38. Weismuller TJ, Lankisch TO (2011) Medical and endoscopic therapy of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 25: 741–752

    Article  PubMed  Google Scholar 

  39. Williamson KD, Chapman RW (2014) Primary sclerosing cholangitis. Dig Dis 32: 438–445

    Article  PubMed  Google Scholar 

  40. Zenouzi R, Weismuller TJ, Hubener P et al (2014) Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 12: 1733–1738

    Article  PubMed  Google Scholar 

Download references

Einhaltung der ethischen Richtlinien

Interessenkonflikt. T.J. Weismüller gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland

    T.J. Weismüller

  2. Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    T.O. Lankisch & T. Voigtländer

Authors
  1. T.J. Weismüller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T.O. Lankisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Voigtländer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T.J. Weismüller.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weismüller, T., Lankisch, T. & Voigtländer, T. Kolonkarzinom und Gallengangskarzinom bei primär sklerosierender Cholangitis. Gastroenterologe 10, 26–31 (2015). https://doi.org/10.1007/s11377-014-0941-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-014-0941-0

Schlüsselwörter

Keywords

Search

Navigation